Implementation study of the CARRA Uveitis Consensus Treatment Plans: feasibility for clinical practice and applicability for research. Pediatric Rheumatology Online Journal. 2024; 22:88.
.S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis. Arthritis Research and Therapy. 2024; 26:125.
.Biomarker Changes in Response to Tofacitinib Treatment in Patients with Polyarticular Course Juvenile Idiopathic Arthritis. Arthritis Care and Research. 2024; 76:1723-1732.
.Validation of the ankle-specific pediatric arthritis ultrasound scoring system in children with juvenile idiopathic arthritis. Seminars in Arthritis and Rheumatism. 2024; 69:152545.
.Interleukin (IL)-1/IL-6-Inhibitor-Associated Drug Reaction With Eosinophilia and Systemic Symptoms (DReSS) in Systemic Inflammatory Illnesses. The Journal of Allergy and Clinical Immunology: in Practice. 2024; 12:2996-3013.e7.
.Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III Study. The Journal of rheumatology. 2024; 51:1125-1134.
.Digital health technology to support patient-centered shared decision making at point of care for juvenile idiopathic arthritis. Frontiers in Pediatrics. 2024; 12:1457538.
.Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study. Annals of the Rheumatic Diseases. 2024; 83:1561-1571.
.Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis. Rheumatology. 2024; 63:2535-2546.
.Renal disease in pediatric rheumatology. Current Opinion in Rheumatology. 2024; 36:322-327.
.Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO/PRCSG registry. Rheumatology. 2024; 63:SI195-SI206.
.Revisiting Childhood-Onset Systemic Lupus Erythematosus. Turkish Archives of Pediatrics. 2024; 59:336-344.
.Comparative Effectiveness of a Second Tumor Necrosis Factor Inhibitor Versus a Non-Tumor Necrosis Factor Biologic in the Treatment of Patients With Polyarticular-Course Juvenile Idiopathic Arthritis. Arthritis Care and Research. 2024; 76:1090-1098.
.Atherosclerosis Progression in the APPLE Trial Can Be Predicted in Young People With Juvenile-Onset Systemic Lupus Erythematosus Using a Novel Lipid Metabolomic Signature. Arthritis and Rheumatology. 2024; 76:455-468.
.The 4th NextGen therapies for SJIA and MAS: part 3 clinical trials in refractory SJIA: historic controls as an alternative to a withdrawal design study. Pediatric Rheumatology Online Journal. 2024; 21:150.
.Efficacy and Safety of Pharmacokinetically-Driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis-A Double-Blind Placebo Controlled Clinical Trial (The Pediatric Lupus Nephritis Mycophenolate Mofetil Study). Journal of Clinical Trials. 2024; 14:563.
.Practice Analysis and Determining the Knowledge and Skills Expected of a Pediatric Rheumatologist. ACR Open Rheumatology. 2023; 5:619-623.
.Health Equity Implications of Missing Data Among Youths With Childhood-Onset Systemic Lupus Erythematosus: A Proof-of-Concept Study in the Childhood Arthritis and Rheumatology Research Alliance Registry. Arthritis Care and Research. 2023; 75:2285-2294.
.Abatacept as Monotherapy and in Combination With Methotrexate in Patients With Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials. The Journal of rheumatology. 2023; 50:1471-1480.
.Long-Term Maintenance of Clinical Responses by Individual Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Abatacept. Arthritis Care and Research. 2023; 75:2259-2266.
.Therapeutic Development in Polyarticular Course Juvenile Idiopathic Arthritis: Extrapolation, Dose Selection, and Clinical Trial Design. Arthritis and Rheumatology. 2023; 75:1856-1866.
.Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce. Nature reviews. Rheumatology. 2023; 19:592-602.
.Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial. The Lancet. 2023; 402:555-570.
.Urine biomarker score captures response to induction therapy with lupus nephritis. Pediatric Nephrology. 2023; 38:2679-2688.
.Patient-Reported Outcomes Among Patients Ages Two to Seventeen Years With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Subcutaneous Abatacept: Two-Year Results From an International Phase III Study. Arthritis Care and Research. 2023; 75:1804-1814.
.Insurance Status and Tumor Necrosis Factor Inhibitor Initiation Among Children With Juvenile Idiopathic Arthritis in the CARRA Registry. The Journal of rheumatology. 2023; 50:1047-1057.
.Treatment patterns in paediatric and adult patients with SLE: a retrospective claims database study in the USA. Lupus Science and Medicine. 2023; 10:e000817.
.Childhood-Onset Lupus Nephritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: Short-Term Kidney Status and Variation in Care. Arthritis Care and Research. 2023; 75:1553-1562.
.2023; 379.2-37380.
. POS0278 EFFICACY AND SAFETY OF SECUKINUMAB IN JUVENILE IDIOPATHIC ARTHRITIS: INTERIM RESULTS FROM THE EXTENSION OF THE JUNIPERA TRIAL.Usefulness of the lupus low disease activity state as a treatment target in childhood-onset SLE. Lupus Science and Medicine. 2023; 10:e000884.
.Preclinical characterization of the Toll-like receptor 7/8 antagonist MHV370 for lupus therapy. Cell Reports Medicine. 2023; 4:101036.
.Acute kidney injury requiring kidney replacement therapy in childhood lupus nephritis: a cohort study of the Pediatric Nephrology Research Consortium and Childhood Arthritis and Rheumatology Research Alliance. Pediatric Nephrology. 2023; 38:1653-1665.
.Evaluating the Construct of Damage in Systemic Lupus Erythematosus. Arthritis Care and Research. 2023; 75:998-1006.
.Disease Recapture Rates After Medication Discontinuation and Flare in Juvenile Idiopathic Arthritis: An Observational Study Within the Childhood Arthritis and Rheumatology Research Alliance Registry. Arthritis Care and Research. 2023; 75:715-723.
.Trajectories of disease activity in patients with JIA in the Childhood Arthritis and Rheumatology Research Alliance Registry. Rheumatology. 2023; 62:804-814.
.Race, ethnicity and patient-reported outcomes in childhood-onset systemic lupus erythematosus. Clinical and Experimental Rheumatology. 2023; 41:186-194.
.Patient-Reported Outcomes Among Transition-Age Young Adults With Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry. The Journal of rheumatology. 2023; 50:98-106.
.Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. Annals of the Rheumatic Diseases. 2023; 82:154-160.
.Springer Nature; Springer Nature; 2023.
. Systemic Lupus Erythematosus. A Clinician's Pearls & Myths in Rheumatology. :Social determinants of health influence disease activity and functional disability in Polyarticular Juvenile Idiopathic Arthritis. Pediatric Rheumatology Online Journal. 2022; 20:18.
.Baseline characteristics of children with juvenile dermatomyositis enrolled in the first year of the new Childhood Arthritis and Rheumatology Research Alliance registry. Pediatric Rheumatology Online Journal. 2022; 20:50.
.In: Donnelly LF, Ed. Diagnostic imaging. Pediatrics. Salt Lake City, Utah: Springer Nature; 2022.
. Juvenile idiopathic arthritis.Alternative Biologic Therapy in Children Failing Conventional TNFα Inhibitors for Refractory, Noninfectious, Chronic Anterior Uveitis. American Journal of Ophthalmology. 2022; 244:183-195.
.Intraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry. Pediatric Rheumatology Online Journal. 2022; 20:107.
.2022; 33:961-962.
. Stability of Novel Urinary Biomarkers Used for Lupus Nephritis. Journal of the American Society of Nephrology : JASN.Cross-cultural adaptation and initial validation of the Brazilian-Portuguese version of the pediatric automated neuropsychological assessment metrics. Frontiers in Psychology. 2022; 13:945425.
.Treatment Guidelines in Pediatric Rheumatic Diseases. Rheumatic Disease Clinics of North America. 2022; 48:725-746.
.Stability of novel urinary biomarkers used for lupus nephritis. Frontiers in Pediatrics. 2022; 10:974049.
.Children With Enthesitis-Related Arthritis and Possible Benefits From Treatments for Adults With Spondyloarthritis. Arthritis Care and Research. 2022; 74:1058-1064.
.Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial. Annals of the Rheumatic Diseases. 2022; 81:990-997.
.2022; 81:145-146.
. OP0221 EFFICACY OF SECUKINUMAB IN ENTHESITIS-RELATED ARTHRITIS: RESULTS FROM A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TREATMENT WITHDRAWAL, PHASE 3 STUDY (JUNIPERA). Annals of the Rheumatic Diseases.2022; 81:422.2-42423.
. POS0340 PREDICTORS OF CLINICAL RESPONSE TO ABATACEPT IN CHILDREN WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS. Annals of the Rheumatic Diseases.Tofacitinib for juvenile idiopathic arthritis - Authors' reply. The Lancet. 2022; 399:1866.
.Clinical measurement of lupus nephritis activity is inferior to biomarker-based activity assessment using the renal activity index for lupus nephritis in childhood-onset systemic lupus erythematosus. Lupus Science and Medicine. 2022; 9:e000631.
.The Geospatial Distribution of Myositis and Its Phenotypes in the United States and Associations With Roadways: Findings From a National Myositis Patient Registry. Frontiers in Medicine. 2022; 9:842586.
.Biomarkers in Childhood-Onset Systemic Lupus Erythematosus. Rheumatic Disease Clinics of North America. 2022; 48:271-285.
.International Consensus for the Dosing of Corticosteroids in Childhood-Onset Systemic Lupus Erythematosus With Proliferative Lupus Nephritis. Arthritis and Rheumatology. 2022; 74:263-273.
.Hydroxychloroquine blood levels predicts flare in childhood-onset lupus nephritis. Lupus. 2022; 31:97-104.
.Impact of the Season of Birth on the Development of Juvenile Idiopathic Arthritis in the United States: A Nationwide Registry-based Study. The Journal of rheumatology. 2021; 48:1856-1862.
.Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry. Pediatric Rheumatology Online Journal. 2021; 19:131.
.Community poverty level influences time to first pediatric rheumatology appointment in Polyarticular Juvenile Idiopathic Arthritis. Pediatric Rheumatology Online Journal. 2021; 19:122.
.Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. The Lancet. 2021; 398:1984-1996.
.2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Science and Medicine. 2021; 8:e000538.
.Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis. Rheumatology. 2021; 60:4495-4507.
.Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis. Rheumatology. 2021; 60:4568-4580.
.Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans. Arthritis and Rheumatology. 2021; 73:1898-1909.
.Clinicopathologic Conference: A Four-Year-Old Child With Digital Clubbing. Arthritis Care and Research. 2021; 73:1379-1386.
.Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study. Arthritis and Rheumatology. 2021; 73:1910-1920.
.2021; 32:610.
. Renal Activity Index in Lupus (RAIL) Score Distinguishes Responder and Non-Responder in Pediatric Lupus Nephritis. Journal of the American Society of Nephrology : JASN.Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison. RMD Open. 2021; 7:e001747.
.Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis. Arthritis Care and Research. 2021; 73:1264-1274.
.Biologic Switching Among Nonsystemic Juvenile Idiopathic Arthritis Patients: A Cohort Study in the Childhood Arthritis and Rheumatology Research Alliance Registry. The Journal of rheumatology. 2021; 48:1322-1329.
.Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis. The Journal of rheumatology. 2021; 48:1073-1081.
.Evolution in the Understanding of Pediatric-Onset Axial Spondyloarthritis. Arthritis Care and Research. 2021; 73:921-923.
.Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Sacroiliitis. Arthritis Care and Research. 2021; 73:940-946.
.Successful Urine Multiplex Bead Assay to Measure Lupus Nephritis Activity. Kidney International Reports. 2021; 6:1949-1960.
.Relationship Between Genetic Risk and Age of Diagnosis in Systemic Lupus Erythematosus. The Journal of rheumatology. 2021; 48:852-858.
.Inflammatory Bowel Disease in Children With Systemic Juvenile Idiopathic Arthritis. The Journal of rheumatology. 2021; 48:567-574.
.Performance of the New 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in Children and Young Adults. Arthritis Care and Research. 2021; 73:580-585.
.Prevalence of autoimmune diseases and other associated conditions in children and young adults with juvenile idiopathic arthritis. RMD Open. 2021; 7:e001435.
.Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial. Arthritis and Rheumatology. 2021; 73:530-541.
.Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open-Label, Randomized Study. Arthritis and Rheumatology. 2021; 73:336-346.
.Springer Nature; Springer Nature; 2021.
. Metrics and Outcome Measures of Disease Activity and Damage in Childhood-Onset Systemic Lupus Erythematosus. Outcome Measures and Metrics in Systemic Lupus Erythematosus. :Immunomodulatory effects of cytokine-induced expansion of cytotoxic lymphocytes in a mouse model of lupus-like disease. Cytotherapy (Informa). 2021; 23:37-45.
.PK/PD Study of Mycophenolate Mofetil in Children With Systemic Lupus Erythematosus to Inform Model-Based Precision Dosing. Frontiers in Pharmacology. 2020; 11:605060.
.Patient and physician discordance of global disease assessment in juvenile dermatomyositis: findings from the Childhood Arthritis & Rheumatology Research Alliance Legacy Registry. Pediatric Rheumatology Online Journal. 2020; 18:5.
.Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2-5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept. Pediatric Rheumatology Online Journal. 2020; 18:19.
.Cerebral microvascular and microstructural integrity is regionally altered in patients with systemic lupus erythematosus. Arthritis Research and Therapy. 2020; 22:135.
.Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study. Arthritis and Rheumatology. 2020; 72:2147-2158.
.The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: a retrospective analysis. Pediatric Rheumatology Online Journal. 2020; 18:7.
.Prevalence of co-existing autoimmune disease in juvenile idiopathic arthritis: a cross-sectional study. Pediatric Rheumatology Online Journal. 2020; 18:43.
.Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis. Pediatric Drugs. 2020; 22:653-672.
.Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials. Arthritis Research and Therapy. 2020; 22:211.
.Association of Ultraviolet Radiation Exposure With Dermatomyositis in a National Myositis Patient Registry. Arthritis Care and Research. 2020; 72:1636-1644.
.2020; 31:553.
. Renal Activity Index for Lupus Nephritis Distinguishes Active Renal Disease Among Lupus Patients. Journal of the American Society of Nephrology : JASN.Quality of Care in Childhood-onset Systemic Lupus Erythematosus: Report of an Intervention to Improve Cardiovascular and Bone Health Screening. The Journal of rheumatology. 2020; 47:1506-1513.
.Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Annals of the Rheumatic Diseases. 2020; 79:1340-1348.
.Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results. Arthritis Care and Research. 2020; 72:1420-1430.
.Proceedings from the 2nd Next Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3-4, 2019. Pediatric Rheumatology Online Journal. 2020; 18:53.
.Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate. RMD Open. 2020; 6:e001208.
.Therapeutic Targeting of Follicular T Cells with Chimeric Antigen Receptor-Expressing Natural Killer Cells. Cell Reports Medicine. 2020; 1:100003.
.Timing matters: real-world effectiveness of early combination of biologic and conventional synthetic disease-modifying antirheumatic drugs for treating newly diagnosed polyarticular course juvenile idiopathic arthritis. RMD Open. 2020; 6:e001091.
.In: Davidson P; Faustino VS; Lamb SE; Lou W; Mangoni AA; Piantadosi S; Schmid C; Teixeira-Pinto A, Ed. SAGR Research Methods Cases. Washington, DC: Sage; 2020.
. Comparative Effectiveness Research Using Electronic Health Records Data: Ensure Data Quality.